The global insulin market size was estimated at USD 20.35 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 1.5% from 2022 to 2030. The insulin market is witnessing growth due to factors such as the increasing incidence of diabetes and formulation advancements. However, the increasing prescription of drugs such as GLP-1 RAs to treat type 2 diabetes can slow down market growth. It is an oligopolistic space dominated by companies like Novo Nordisk A/S, Sanofi, and Eli Lilly and Company. Diabetes is one of the fastest-growing chronic diseases in the world. Its prevalence has increased steadily over the past few decades. The World Health Organization estimates that 537 million adults worldwide affected by diabetes in 2021, and one in ten experienced other diabetes.
In addition, geriatric and obese populations are more susceptible to chronic diseases. According to the World Bank Group, in 2020, the global elderly population was around 727 million, which is expected to double over the next three decades, reaching approximately 1.5 billion in 2050.
Formulation advancements are another crucial factor driving space growth. For instance, Fiasp (Novo Nordisk) is a formulation of insulin aspart in a combination of niacinamide (Vitamin-B3), which can improve the initial absorption of the drug. Afrezza (Mannkind) is the only inhaled form available in the market, which eliminates the need for needles & syringes.Moreover, Oramed Pharmaceuticals' oral insulin capsule is undergoing phase 3 clinical trials. The company is expected to submit the BLA by Q4 2023. The successful launch of this product can provide an alternative option to patients.
The market saw a setback due to the COVID-19 pandemic. Amid the pandemic, slowdown and disruption in the supply of pharmaceuticals were observed due to the strategies designed to control the spread of SARS-CoV-2. In addition, hospitals have reported a decrease in the number of insulin prescriptions. However, in several countries, the effect of COVID-19 declined to post the second quarter of 2021, which helped the market regain traction.
The high cost of insulin could impede the market growth. Leading players such as Eli Lilly and Company, Novo Nordisk A/S, and Sanofi have patent protection for products. For instance, Sanofi filed 74 patent applications for Admelog to strengthen its position. These companies hold more than 90% of the global market. As a result, biosimilar players are negligible in this space.
The long-acting insulin segment contributed a substantial revenue share of 56.53% in 2021. Factors such as patent protection and high demand due to long-term effects are expected to drive the segment. Toujeo, Levemir, Xultophy, Insulatard, and Lantus are among the major products in this segment. In comparison, rapid-acting insulin results in faster absorption. Key products in this segment include aspart, lispro, and glulisine. Among them, Lispro dominated, with the highest sales in 2021.
The Biosimilar insulin segment is expected to expand at a lucrative CAGR of 18.3% during the forecast period. The patent expiry for major products and subsequent availability and uptake of biosimilar insulin products will drive segment growth. For instance, in July 2021, Semglee, a glargine biosimilar, was approved by the FDA. It was the first insulin biosimilar in the U.S. and was also approved as an interchangeable biosimilar of Lantus.
In 2021, the largest segment by application is type 1 diabetes mellitus, due to the high insulin dependency of these patients. It is a more severe condition than type 2 diabetes. According to the International Diabetes Federation, around 10% of all individuals with diabetes have type-1 diabetes.
Type 2 diabetes mellitus is expected to be the fastest-growing segment. It is the most common type across the globe. Its high prevalence is the primary reason for the segment's growth. According to the IDF 2021 report, the prevalence of type 2 diabetes was around 405.6 million, which is projected to increase to approximately 510.8 million by 2030. Several companies are engaged in the R&D of oral insulin. So far, the FDA has approved only two systems for oral delivery of insulin: Oramed’s ORMD-0801 and Diasome’s HDV-I. ORMD-0801 is under phase 3 clinical trial. The approval of this product will provide patients with an add-on option to insulin injections.
The analog insulin segment dominated the market with a share of 86.58% in 2021. Its dominance can be attributed to the higher efficacy of insulin and minimal adverse effects, such as hypoglycemic attacks and lower weight gain, as compared to conventional therapy. Long-acting insulin products dominate the market. Long-acting insulin analogs like glargine, detemir, and degludec are developed by companies Eli Lilly, Novo Nordisk A/S, and Sanofi, respectively. These products have a high market share, and their demand is expected to drive the market.
In contrast, human insulin is a traditional form of insulin. The big three manufacturers have products like Humulin, Insuman, and Novolog in the market. However, owing to the presence of more effective insulin analogs, the sales and prescription rate of these products are expected to decline over the forthcoming years.
The retail pharmacy segment dominated the overall market in 2021, owing to the rising burden of disease, the feasibility of home care patients, and various discounts offered by retail pharmacies. The market has witnessed consolidation in retail pharmacy chains in the United States. Furthermore, the hospital pharmacy segment is expected to grow moderately. This segment is driven by factors such as the rising hospitalization of diabetic patients.
The others segment includes online pharmacies that are anticipated to witness the fastest growth during the forecast period. The comfort, flexibility, and convenience provided by online purchase of medications are major factors driving the segment. In addition, the discounts offered by online pharmacies attract patients to purchase medications online, which is also expected to fuel market growth.
North America dominated the space in terms of revenue in 2021, mainly due to the dominance of branded products and the increasing prevalence of disease in the region. According to the CDC, approximately 37.3 million people in the United States had diabetes in 2020, with 28.7 million diagnosed and 8.5 million undiagnosed cases. Furthermore, about 96 million people aged 18 years and older have prediabetes. Some of the major players currently operating in this region include Novo Nordisk A/S, Eli Lilly and Company, and Sanofi. However, the U.S. FDA has approved two new insulin biosimilars, Semglee and Rezvoglar, from Mylan/Biocon and Eli Lilly and Company, respectively. The entry of these biosimilars is expected to drive down the price of insulin in the U.S. market and intensify the competition.
Asia Pacific is expected to witness significant growth during the forecast period, owing to factors such as rising geriatric & target populations, increasing number of collaborations for the development of biosimilars, geographic expansion of key players, and active participation of government & nonprofit organizations in the market space. Furthermore, health awareness campaigns and scientific conferences for the management of this disease may fuel market growth in the region.
Many companies are rapidly opting for geographical expansion, strategic collaborations, and partnerships in emerging and economically favorable regions through mergers and acquisitions. For instance, in February 2022, Biocon announced the acquisition of Viatris’ biosimilar portfolio for USD 3.335 billion. This acquisition strengthened Biocon’s biosimilar product portfolio and improved its revenue generation. Some of the prominent key players in the global insulin market include:
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Biocon Ltd
Wockhardt
Boehringer Ingelheim International GmbH
Julphar
United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co. Ltd.
Report Attribute |
Details |
Market size value in 2022 |
USD 20.18 billion |
Revenue forecast in 2030 |
USD 23.20 billion |
Growth rate |
CAGR of 1.5% from 2022 to 2030 |
Base year for estimation |
2021 |
Historical data |
2018 - 2020 |
Forecast period |
2022 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2022 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product type, application, type, distribution channel, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; U.K.; France; Italy; Spain; China; Japan; India; Australia; South Korea; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Eli Lilly and Company; Sanofi; Novo Nordisk A/S; Biocon; Boehringer Ingelheim; Tonghua Dongbao Pharmaceutical Co. Ltd; Wockhardt; Julphar; United Laboratories International Holdings Limited |
Customization scope |
Free report customization (equivalent to up to 8 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the insulin market based on product type, application, type, distribution channel, and regions.
Product Type Outlook (Revenue, USD Million, 2018 - 2030)
Rapid-Acting Insulin
Long-Acting Insulin
Combination Insulin
Biosimilar
Others
Type Outlook (Revenue, USD Million, 2018 - 2030)
Human Insulin
Insulin Analog
Application Outlook (Revenue, USD Million, 2018 - 2030)
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Retail Pharmacies
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Asia Pacific
Japan
China
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
b. The global insulin market size was valued at USD 20.35 billion in 2021 and is anticipated to reach USD 20.18 billion in 2022.
b. The global insulin market is expected to witness a compound annual growth rate of 1.5% from 2022 to 2030 to reach USD 23.20 billion by 2030.
b. Based on product type, the long-acting insulin segment accounted for a share of 56.53% in 2021 due to high prescription rate owing the longer duration of effect and lesser amount of injections required.
b. Some of the key players in the insulin market are Novo Nordisk A/S; Eli Lilly and Company; Sanofi; Biocon Ltd; Wockhardt; Boehringer Ingelheim International GmbH; Julphar; United Laboratories International Holdings Limited; and Tonghua Dongbao Pharmaceutical Co. Ltd.
b. The major factors driving market growth are the rising prevalence of diabetes, rising geriatric and obese population base, and advancements in insulin delivery.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."